Intas Pharma plans to launch its first biosimilar in US: Reports - (India Infoline via NewsPoints Desk)

  • Intas Pharmaceuticals expects to launch its first biosimilar in the US within nine to 12 months, India Infoline reported Monday.
  • The company's first biosimilar Accofil (filgratsim) was launched in Europe earlier this year, while Intas has also launched Razumab, a biosimilar version of Lucentis, in India.

To read more NewsPoints articles, click here.